CR20210103A - Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 - Google Patents
Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5Info
- Publication number
- CR20210103A CR20210103A CR20210103A CR20210103A CR20210103A CR 20210103 A CR20210103 A CR 20210103A CR 20210103 A CR20210103 A CR 20210103A CR 20210103 A CR20210103 A CR 20210103A CR 20210103 A CR20210103 A CR 20210103A
- Authority
- CR
- Costa Rica
- Prior art keywords
- related disease
- prevention
- treating
- preventing
- treatment
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención se refiere a composiciones farmacéuticas para usarse en el tratamiento o prevención de una enfermedad relacionada con C5 y métodos para tratar o 5 prevenir una enfermedad relacionada con C5. La presente invención además se refiere a dosificaciones y administraciones de anticuerpo anti-C5 o composiciones farmacéuticas que contienen el anticuerpo.</p>
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713211P | 2018-08-01 | 2018-08-01 | |
US201862764952P | 2018-08-17 | 2018-08-17 | |
US201862760204P | 2018-11-13 | 2018-11-13 | |
PCT/JP2019/030283 WO2020027279A1 (en) | 2018-08-01 | 2019-08-01 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210103A true CR20210103A (es) | 2021-03-22 |
Family
ID=67660420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210103A CR20210103A (es) | 2018-08-01 | 2019-08-01 | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210301004A1 (es) |
EP (1) | EP3829628B1 (es) |
JP (3) | JP6672516B2 (es) |
KR (4) | KR20210038697A (es) |
CN (1) | CN112512563A (es) |
AU (1) | AU2019315213B2 (es) |
BR (1) | BR112021001655A2 (es) |
CA (1) | CA3107618A1 (es) |
CR (1) | CR20210103A (es) |
DE (1) | DE112019003835T5 (es) |
IL (1) | IL280475A (es) |
MX (1) | MX2021000516A (es) |
PH (1) | PH12021550226A1 (es) |
SG (1) | SG10202002898RA (es) |
TW (2) | TWI701041B (es) |
WO (1) | WO2020027279A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
DK2275443T3 (en) | 2008-04-11 | 2016-02-08 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repetitively binding to two or more antigen molecules |
KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
IL264626B (en) | 2016-08-05 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | A preparation for the prevention or treatment of diseases related to il-8 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01007170A (es) | 1999-01-15 | 2002-07-30 | Genentech Inc | Variantes de polipeptidos con funcion efectora alterada. |
DK1325033T3 (da) | 2000-10-10 | 2010-04-06 | Genentech Inc | Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning |
MX342385B (es) | 2001-08-17 | 2016-09-27 | Genentech Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a sin evitar la formación de c5b. |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
EP3167888B1 (en) | 2006-03-15 | 2024-05-01 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
DK2275443T3 (en) | 2008-04-11 | 2016-02-08 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repetitively binding to two or more antigen molecules |
CN102170906B (zh) | 2008-08-05 | 2014-07-30 | 诺华股份有限公司 | 靶定补体蛋白c5的抗体的组合物和方法 |
KR20110094029A (ko) | 2008-11-10 | 2011-08-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체-관련된 장애를 치료하는 방법 및 조성물 |
JP5932670B2 (ja) | 2010-03-11 | 2016-06-08 | ライナット ニューロサイエンス コーポレイション | pH依存性の抗原結合を有する抗体 |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
BR112015018438A2 (pt) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento |
SG10201710322VA (en) * | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
RU2730590C2 (ru) * | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Композиция для лечения заболеваний, связанных с ил-6 |
US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
JP7518764B2 (ja) * | 2017-10-26 | 2024-07-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性***症候群(aHUS)の処置のための抗C5抗体の投薬量および投与 |
WO2019112984A1 (en) * | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
-
2019
- 2019-08-01 US US17/263,691 patent/US20210301004A1/en active Pending
- 2019-08-01 SG SG10202002898RA patent/SG10202002898RA/en unknown
- 2019-08-01 TW TW108127358A patent/TWI701041B/zh active
- 2019-08-01 KR KR1020217009233A patent/KR20210038697A/ko not_active IP Right Cessation
- 2019-08-01 DE DE112019003835.4T patent/DE112019003835T5/de active Pending
- 2019-08-01 CN CN201980051238.8A patent/CN112512563A/zh active Pending
- 2019-08-01 JP JP2019142108A patent/JP6672516B2/ja active Active
- 2019-08-01 WO PCT/JP2019/030283 patent/WO2020027279A1/en active Application Filing
- 2019-08-01 KR KR1020207007296A patent/KR20200033348A/ko active Application Filing
- 2019-08-01 EP EP19755447.0A patent/EP3829628B1/en active Active
- 2019-08-01 CR CR20210103A patent/CR20210103A/es unknown
- 2019-08-01 AU AU2019315213A patent/AU2019315213B2/en active Active
- 2019-08-01 MX MX2021000516A patent/MX2021000516A/es unknown
- 2019-08-01 KR KR1020217009235A patent/KR20210037743A/ko not_active IP Right Cessation
- 2019-08-01 BR BR112021001655-4A patent/BR112021001655A2/pt unknown
- 2019-08-01 KR KR1020197036896A patent/KR20200033225A/ko active Application Filing
- 2019-08-01 TW TW109108378A patent/TWI704157B/zh active
- 2019-08-01 CA CA3107618A patent/CA3107618A1/en active Pending
-
2020
- 2020-02-18 JP JP2020025071A patent/JP6672533B1/ja active Active
- 2020-03-04 JP JP2020036818A patent/JP2020079331A/ja active Pending
-
2021
- 2021-01-28 IL IL280475A patent/IL280475A/en unknown
- 2021-01-29 PH PH12021550226A patent/PH12021550226A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3829628A1 (en) | 2021-06-09 |
KR20200033225A (ko) | 2020-03-27 |
TWI701041B (zh) | 2020-08-11 |
JP2020019769A (ja) | 2020-02-06 |
DE112019003835T5 (de) | 2021-05-27 |
JP6672516B2 (ja) | 2020-03-25 |
TWI704157B (zh) | 2020-09-11 |
JP2020079331A (ja) | 2020-05-28 |
SG10202002898RA (en) | 2020-05-28 |
IL280475A (en) | 2021-03-01 |
TW202019467A (zh) | 2020-06-01 |
EP3829628C0 (en) | 2024-05-15 |
AU2019315213B2 (en) | 2024-05-02 |
WO2020027279A1 (en) | 2020-02-06 |
KR20200033348A (ko) | 2020-03-27 |
US20210301004A1 (en) | 2021-09-30 |
CN112512563A (zh) | 2021-03-16 |
PH12021550226A1 (en) | 2021-10-11 |
JP2020073608A (ja) | 2020-05-14 |
AU2019315213A1 (en) | 2021-03-25 |
MX2021000516A (es) | 2021-04-12 |
CA3107618A1 (en) | 2020-02-06 |
BR112021001655A2 (pt) | 2021-05-04 |
JP6672533B1 (ja) | 2020-03-25 |
TW202024128A (zh) | 2020-07-01 |
KR20210037743A (ko) | 2021-04-06 |
KR20210038697A (ko) | 2021-04-07 |
EP3829628B1 (en) | 2024-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501706A1 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
CR20210103A (es) | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 | |
PH12018500642A1 (en) | Anti-garp antibody | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
NZ722518A (en) | Il-21 antibodies | |
EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
MX2020013621A (es) | Composiciones y metodos de tratamiento de vih. | |
MX2018009504A (es) | Composiciones y metodos para tratar infecciones. | |
MX2020009496A (es) | Metodo para tratar asma o enfermedad alergica. | |
MX2021011986A (es) | Metodos de tratamiento de dolor neuropatico. | |
EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. | |
MX2020007050A (es) | Una combinacion de inmunoglobulina plasmatica e inmunoglobulina especifica de antigeno para la modificacion del sistema inmune y el tratamiento o prevencion de enfermedades alergicas. | |
SG10201705954VA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
MX2021001393A (es) | Composiciones para el tratamiento de la enfermedad de injerto contra huesped. | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
MX2020013923A (es) | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. | |
WO2018030881A3 (ko) | 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도 | |
GB2567398A (en) | Method and composition for treating dysbiosis and related disease states | |
MX2022000317A (es) | Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5. |